Patients with certain KLK-6 mutations at risk for aggressive forms of prostate cancer

A newly published article in the Journal of the National Cancer Institute has suggested that men carrying a particular genetic mutation in the kallikrein 6 gene (KLK-6) have an increased risk for aggressive, clinically significant prostate cancer. … READ MORE …

Early chemotherapy in treatment of high-risk and aggressive prostate cancers?

So the results from the CHAARTED and STAMPEDE trials over the past few years have re-ignited debate over the appropriateness of early use of chemotherapy in the treatment of aggressive forms of prostate cancer. … READ MORE …

Saturated and unsaturated dietary fats and risk for aggressive prostate cancer

A newly published article in Prostate Cancer and Prostatic Diseases has (potentially) expanded our understanding of the role of saturated fats in men’s diets and consequent risk for diagnosis with aggressive forms of prostate cancer. … READ MORE …

Mutation to inherited HSD3B1 gene associated with more aggressive form of prostate cancer

According to an article to appear in the September issue of The Lancet Oncology, some patients with aggressive prostate cancer are more likely to die earlier from their disease if they carry a specific testosterone-related genetic abnormality. … READ MORE …

Risk levels and family history of prostate cancer: data from the Swiss cohort of the ERSPC

Data just published in BJU International have recently suggested that men with a known, positive family history of prostate cancer are certainly at increased risk of low-grade prostate cancer compared to men with no known family history — but not at increased risk of aggressive prostate cancer. … READ MORE …

An aggressive, ETS-negative subtype of prostate cancer

A paper just published in Cancer Research suggests that a particular ETS-negative subtype of prostate cancer (ERGMAP3K7delCHD1del) is highly aggressive, and that coordinate loss of the MAP3K7 and CHD1 genes are potentially a unique driver of development of aggressive prostate cancer. … READ MORE …

The benefit (or lack thereof) of early, aggressive treatment in men ≥ 66 years

A new study published on line in the journal Cancer has shown that (a) the cancer-specific survival benefit associated with aggressive treatment for early-stage prostate cancer is reduced with increasing co-morbidity at time of diagnosis, and (b) patients with Charlson scores ≥ 3 gain no survival benefit from aggressive treatment. … READ MORE …